The active ingredient of N-003 is currently marketed in the US and Europe. The pharmacology of N-003 is well-understood, and significant clinical and experimental experience support a potential role for N-003 in reversing or preventing some types of Acute Kidney Injury (also referred to acute renal failure). Given its broad characterisation in human and experimental use, the development plan for N-003 is short and allows for a targeted development focussing exclusively on the new indications.

N-003 is currently being developed for two orphan renal indications, Delayed Graft Function and Hepatorenal Disorders. These two diseases are conditions where renal vasoconstriction participates in the acute dysfunction of the kidney. N-003 could effectively reverse renal vasoconstriction and increasing renal blood flow.

Developed with the needs of patients in mind, N-003 is a new formulation and is administered through a different route of administration. N-003 could represent a new paradigm for treating some forms of Acute Kidney Injury.